Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
Bullboard Posts
User Avatar Image
(311)
•••
Comment by KILOFINALon Oct 21, 2020 6:26pm
125 Views
Post# 31759400

RE:RE:I'm in no rush for news, there are no " deadlines"

RE:RE:I'm in no rush for news, there are no " deadlines" that's true bcman79. It speaks volumes with the VPT VMS +3 having been remotely installed in the largest cancer center in the USA.

Today I added more shares as it was a great opportunity for me. I'll keep adding and news will come when it comes. I'm in no rush   



bcman79 wrote: Agreed, I'm in it for a while. The technology is just to good. Once they start installing in more hospitals and word starts getting out, then watch out. But all this takes time, I'm starting to notice a lot more inpatient people on here and ceo. Not every stock is a rocket, this stock will turn into one once more hospitals realize what an important tool this is for them not to mention a hell of a lot cheaper than an MRI. IMHO. Anyway tomorrow is another day. GL


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities